Survivin as a diagnostic and therapeutic marker for thyroid cancer.
Biomarker
Survivin
Thyroid cancer
Journal
Pathology, research and practice
ISSN: 1618-0631
Titre abrégé: Pathol Res Pract
Pays: Germany
ID NLM: 7806109
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
received:
06
08
2018
revised:
28
12
2018
accepted:
17
01
2019
pubmed:
27
1
2019
medline:
14
6
2019
entrez:
27
1
2019
Statut:
ppublish
Résumé
Thyroid cancer (TC) is known as the most prevalent form of endocrine malignancy. With regard to high heterogeneity of the nodules, problem of discriminating between benign and malignant ones in terms of pathological characteristics, as well as lack of appropriate molecular markers; significant efforts are being made to identify molecular markers that able to detect tumorous lesions. Survivin, the newest member of the family of proteins inhibiting cell apoptosis, has been recently considered as a novel molecule marker for cancer. Studies on TC have also demonstrated distinctive expression of survivin and its splice variants in cancer cells compared to normal ones. Therefore, detection of survivin expression and its new splice variants can be utilized to identify tumor nodules and distinguish them from non-cancerous ones, along with other routine laboratory methods.
Identifiants
pubmed: 30683476
pii: S0344-0338(18)31002-1
doi: 10.1016/j.prp.2019.01.025
pii:
doi:
Substances chimiques
BIRC5 protein, human
0
Biomarkers, Tumor
0
Survivin
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
619-625Informations de copyright
Copyright © 2019. Published by Elsevier GmbH.